Jpmorgan Chase & CO Arcellx, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACLX
# of Institutions
205Shares Held
44.2MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$328 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$319 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$308 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$289 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$202 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.6B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...